Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.

Sen-Martín L, Fernández-Trasancos Á, López-Unzu MÁ, Bak A, Zafra-Castellano M, Srikantharajah R, Pathak D, Klotz A, Kuehn MN, Ferrarini A, Labrador-Cantarero V, Sánchez-Ortiz D, Pricolo MR, Vicente N, Velázquez-Carreras D, Sánchez-García L, Sicilia J, Nicolás-Ávila JÁ, Sánchez-Díaz M, Schlossarek S, Cussó L, Desco M, Villalba-Orero M, Guzmán-Martínez G, Calvo E, Barriales-Villa R, Vázquez J, Sánchez-Cabo F, Hidalgo A, de Tombe PP, Carrier L, Spudich JA, Ruppel KM, Weinberger F, Cazorla O, Hessel AL, Alegre-Cebollada J.

Open source

DOI
10.1038/s44161-026-00833-3
Published
2026-07-07
Container
Nat Cardiovasc Res
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s44161-026-00833-3,
  title = {Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.},
  author = {Sen-Martín L and  Fernández-Trasancos Á and  López-Unzu MÁ and  Bak A and  Zafra-Castellano M and  Srikantharajah R and  Pathak D and  Klotz A and  Kuehn MN and  Ferrarini A and  Labrador-Cantarero V and  Sánchez-Ortiz D and  Pricolo MR and  Vicente N and  Velázquez-Carreras D and  Sánchez-García L and  Sicilia J and  Nicolás-Ávila JÁ and  Sánchez-Díaz M and  Schlossarek S and  Cussó L and  Desco M and  Villalba-Orero M and  Guzmán-Martínez G and  Calvo E and  Barriales-Villa R and  Vázquez J and  Sánchez-Cabo F and  Hidalgo A and  de Tombe PP and  Carrier L and  Spudich JA and  Ruppel KM and  Weinberger F and  Cazorla O and  Hessel AL and  Alegre-Cebollada J.},
  year = {2026},
  journal = {Nat Cardiovasc Res},
  doi = {10.1038/s44161-026-00833-3},
  url = {https://doi.org/10.1038/s44161-026-00833-3}
}

RIS

TY  - JOUR
TI  - Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.
AU  - Sen-Martín L
AU  -  Fernández-Trasancos Á
AU  -  López-Unzu MÁ
AU  -  Bak A
AU  -  Zafra-Castellano M
AU  -  Srikantharajah R
AU  -  Pathak D
AU  -  Klotz A
AU  -  Kuehn MN
AU  -  Ferrarini A
AU  -  Labrador-Cantarero V
AU  -  Sánchez-Ortiz D
AU  -  Pricolo MR
AU  -  Vicente N
AU  -  Velázquez-Carreras D
AU  -  Sánchez-García L
AU  -  Sicilia J
AU  -  Nicolás-Ávila JÁ
AU  -  Sánchez-Díaz M
AU  -  Schlossarek S
AU  -  Cussó L
AU  -  Desco M
AU  -  Villalba-Orero M
AU  -  Guzmán-Martínez G
AU  -  Calvo E
AU  -  Barriales-Villa R
AU  -  Vázquez J
AU  -  Sánchez-Cabo F
AU  -  Hidalgo A
AU  -  de Tombe PP
AU  -  Carrier L
AU  -  Spudich JA
AU  -  Ruppel KM
AU  -  Weinberger F
AU  -  Cazorla O
AU  -  Hessel AL
AU  -  Alegre-Cebollada J.
PY  - 2026
JO  - Nat Cardiovasc Res
DO  - 10.1038/s44161-026-00833-3
UR  - https://doi.org/10.1038/s44161-026-00833-3
ER  -

APA

L, S., Á, F., MÁ, L., A, B., M, Z., R, S., D, P., A, K., MN, K., A, F., V, L., D, S., MR, P., N, V., D, V., L, S., J, S., JÁ, N., M, S., S, S., L, C., M, D., M, V., G, G., E, C., R, B., J, V., F, S., A, H., PP, D. T., L, C., JA, S., KM, R., F, W., O, C., AL, H., & J., A. (2026). Mavacamten shows broad benefit in human and mouse models of MYBPC3-related hypertrophic cardiomyopathy.. Nat Cardiovasc Res. https://doi.org/10.1038/s44161-026-00833-3

Source records